Acute and chronic hormone and metabolite changes in lambs fed the beta-agonist, cimaterol

Lubabegron fumarate acts as a β-adrenergic receptor antagonist in cultured bovine intramuscular and subcutaneous adipocytes

We hypothesized that lubabegron fumarate (LUB) (Experior, Elanco Animal Health, Greenfield, IN) would act as an antagonist to β-adrenergic receptor (β-AR) subtypes in primary bovine subcutaneous (s.c.) and intramuscular (i.m.) adipocytes differentiated in culture. This study employed LUB, dobutamine (DOB, a selective β1-agonist), salbutamol (SAL, a selective β2-agonist), and propranolol (PRO, a non-selective β-AR antagonist). Preadipocytes were isolated by standard techniques from bovine longissimus muscle and overlying s.c. adipose tissue and differentiated to adipocytes for 14 d. The adipocyte source x stage of differentiation interaction was significant for β-adrenergic receptors-1 (ADRB1) (P = 0.001) and ADRB2 (P = 0.01) in that expression of ADRB1 and ADRB2 was greater in s.c. adipocytes than in s.c. preadipocytes; expression of the ADRB1-3 did not change after differentiation of i.m. adipocytes. CCATT/enhancer-binding protein alpha (CEBPA) expression increased upon differentiation in both s.c. and i.m. adipocytes (P = 0.006). The source x stage of differentiation interaction was significant for peroxisome proliferator-activated receptor gamma (PPARG) (P ≤ 0.001) and fatty acid binding protein-4 (FABP4) (P = 0.004). Expression of PPARG increased after differentiation of s.c. preadipocytes to adipocytes, but PPARG expression did not change with differentiation of i.m. preadipocytes to adipocytes. FABP4 expression increased after differentiation of both s.c. and i.m. adipocytes, but FABP4 expression increased to a greater extent in s.c. adipocytes. In s.c. adipocytes, DOB elevated cAMP and glycerol production and protein kinase A (PKA) activity, and SAL increased PKA activity; these effects were abolished by LUB and PRO (P < 0.001). Incubation of i.m. adipocytes with SAL increased cAMP production and PKA activity, which was attenuated by LUB and PRO (P ≤ 0.006). In s.c. adipocytes, SAL, LUB + SAL, and LUB + DOB upregulated hormone sensitive lipase (HSL) (P < 0.001) and perilipin (P = 0.002) gene expression. In i.m. adipocytes, DOB and LUB + DOB increased HSL gene expression (P = 0.001) and LUB + SAL depressed adipose triglyceride lipase expression below control levels (P = 0.001). These results demonstrate that LUB is a β-AR antagonist at the β1-AR and β2-AR subtypes in s.c. adipocytes, and that s.c. and i.m. exhibit different responses to β-AA and LUB.

Differential effects of short-term β agonist and growth hormone treatments on expression of myosin heavy chain IIB and associated metabolic genes in sheep muscle

Growth hormone (GH) and β agonists increase muscle mass, but the mechanisms for this response are unclear and the magnitude of response is thought to vary with age of animal. To investigate the mechanisms driving the muscle response to these agents, we examined the effects of short-term (6 day) administration of GH or cimaterol (a β2-adrenergic agonist, BA) on skeletal muscle phenotype in both young (day 60) and mature (day 120) lambs. Expression of myosin heavy chain (MyHC) isoforms were measured in Longissimus dorsi (LD), Semitendinosus (ST) and Supraspinatus (SS) muscles as markers of fibre type and metabolic enzyme activities were measured in LD. To investigate potential mechanisms regulating the changes in fibre type/metabolism, expression or activity of a number of signalling molecules were examined in LD. There were no effects of GH administration on MyHC isoform expression at either the mRNA or protein level in any of the muscles. However, BA treatment induced a proportional change in MyHC mRNA expression at both ages, with the %MyHCI and/or IIA mRNA being significantly decreased in all three muscles and %MyHCIIX/IIB mRNA significantly increased in the LD and ST. BA treatment induced de novo expression of MyHCIIB mRNA in LD, the fastest isoform not normally expressed in sheep LD, as well as increasing expression in the other two muscles. In the LD, the increased expression of the fastest MyHC isoforms (IIX and IIB) was associated with a decrease in isocitrate dehydrogenase activity, but no change in lactate dehydrogenase activity, indicating a reduced capacity for oxidative metabolism. In both young and mature lambs, changes in expression of metabolic regulatory factors were observed that might induce these changes in muscle metabolism/fibre type. In particular, BA treatment decreased PPAR-γ coactivator-1β mRNA and increased receptor-interacting protein 140 mRNA. The results suggest that the two agents work via different mechanisms or over different timescales, with only BA inducing changes in muscle mass and transitions to a faster, less oxidative fibre type after a 6-day treatment.

Reduced response to an estrous induction program in postpartum beef cows treated with zilpaterol and gaining body weight

In beef cows, reduced energy intake delays first ovulation postpartum and is associated with lesser insulin, IGF-I and leptin concentrations. However, the close relationship among these hormones mask their individual roles in the reinitiation of ovarian activity. A β-adrenergic receptor agonist (βAR) was used to increase body condition score (BCS) and yet reduce body fat and leptin serum concentration to determine the specific role of leptin in the postpartum ovarian activity. Beef cows (n=77) with BCS 3.1 ± 1.4 received 2 kg/day of feed containing 0 or 0.15 mg/kg of zilpaterol (a synthethic βAR), for 33 days. Estrus was induced with a progestin implant applied for 9 d and cows in estrus were bred by artificial insemination (AI). Zilpaterol administration increased (P<0.05) daily weight gain, muscle depth and BCS, with no changes in back fat depth, reducing fat to muscle ratio (P<0.05). At the time of AI, insulin (38%) and IGF-I (26%) concentrations were less in zilpaterol-treated cows (P<0.05), but leptin concentration was unaffected. Ovulation rate and animal with luteal activity after estrus induction were also reduced by 35% (P=0.05) and 56.5% (P=0.007), respectively, in zilpaterol-treated cows. Logistic regression estimates for BCS (P=0.016) and IGF-I concentration (P=0.03) were positively related with the occurrence of luteal activity. In addition, whilst back fat (P=0.009) had a positive effect on luteal activity, leptin concentration did not show a significant relationship. In conclusion, despite an increase in body weight and a positive change in BCS, the reduction in insulin and IGF-I concentrations, associated with βAR treatment, reduced the response to induction of estrus. However only IGF-I, but not leptin or insulin, significantly influenced the odds for the occurrence of luteal activity after estrous induction in cattle with poor BCS.

Effects of the β2 -agonist clenbuterol on testicular steroidogenic acute regulatory protein mRNA expression in adult rats

This study was carried out to investigate the effects of clenbuterol (CLB) on the testicular (steroidogenic acute regulatory, StAR) protein mRNA expression in rats. Thirty adult male rats were administered CLB by gavage daily at the doses of 0.4, 2.0 and 18.5 mg/kg bw for 14 days in the subacute experiment, whereas 20 rats received a single treatment with CLB at the doses of 20 and 40 mg/kg bw in the acute experiment and 20 rats were treated with 0.9% NaCl solution as vehicle groups. Testicular tissues were collected and snap-frozen in liquid nitrogen and stored at -70 °C until use. The levels of StAR mRNA were detected by RT-PCR. The levels of StAR mRNA were markedly increased (P < 0.05) at both dosages of 20 and 40 mg/kg bw but the effects were not dose-dependent and the mRNA levels of StAR were returned to near normal level after 7 days of CLB withdrawal, compared with the control animals. In the subacute experiment, CLB induced a dose-dependent but no statistical significant reduction (P > 0.05) in the expression levels of StAR mRNA, and the mRNA levels were recovered to near normal level in the groups treated with CLB at dosages of 0.4 and 2.0 mg/kg bw/day following a 7-day withdrawal period, compared with the control animals. The mRNA levels of StAR showed a significant decrease in the groups treated with CLB at the dosage of 18.5 mg/kg bw/day (P < 0.05) after a 1- or 7-day withdrawal period with respect to the control animals. These results demonstrated transient stimulative effects of CLB on testicular StAR mRNA levels and inhibitory effects after treatment with CLB for 14 consecutive days.

The effect of immunization against somatostatin and β-agonist administration alone and in combination on growth and carcass composition in young steers

The effect of active immunization against somatostatin and β-agonist administration alone and in combination on growth, carcass composition and endocrine responses was investigated in young steers given a pelleted diet of dried grass and barley (0·7: 0·3) ad libitum for 16 weeks. Immunization alone increased growth rate by proportionately 0·10 but had no effect on plasma growth hormone (GH) or insulin-like growth factor-1 (IGF-1) concentrations (P > 0·10). Carcass protein content was unchanged but fat content tended to be increased. This was possibly associated with increased (P < 0·10) plasma insulin concentrations observed in these animals. Cimaterol administration significantly increased growth rate (P < 0·05) and carcass weight (P < 0·01). Carcass protein content was significantly (P < 0·01) increased and carcass fat was significantly (P < 0·001) reduced. Administration of cimaterol to immunized animals resulted in an enhancement of the repartitioning effect of the pagonist although growth rates were intermediate between the separate treatments. The mechanism by which this was achieved is unclear. Plasma IGF-1 concentrations tended (P < 0·10) to be lower in these animals compared with controls. Plasma insulin concentrations were also reduced (P < 0·05) in these animals. Both immunized animals and those given cimaterol alone showed an increased GH response to a single intravenous injection of growth hormone releasing factor (GRF) (P < 0·05). Animals given the combined treatment however showed a reduced response suggesting that the effects were not mediated through direct changes in GH secretion. The improved lean:fat ratio in the carcass was observed to be mediated through an enhancement of the lipolytic response to the /J-agonist with only small effects on protein accretion. It is suggested that immunoneutralization of somatostatin may increase the sensitivity of adipose tissue to lipolytic stimuli. This could occur through changes in the secretion of gastrointestinal or pancreatic hormones as a result of neutralization of the inhibitory influences of somatostatin. Further work is required to clarify these effects.

Change in insulin sensitivity or responsiveness is not a major component of the mechanism of action of ractopamine in beef steers

Our objective was to determine whether the beta-adrenergic agonist ractopamine altered sensitivity or responsiveness to insulin. We used the hyperinsulinemic, euglycemic clamp approach in five multicatheterized beef steers to evaluate insulin sensitivity (ED50) and responsiveness (Rmax or Rmin) during control or ractopamine feeding (80 mg/kg feed). Steers had blood vessel catheters and ultrasound flow probes that allowed measurement of net uptake and release of glucose and insulin by portal-drained viscera (PDV), liver and hindlimb. Steers ate meals of equal size every 2 h. Steers were fed at 1.8 times calculated maintenance energy. The design was a single reversal. Two rates of insulin infusion followed a base-line period on each of three sample days. Insulin was infused into a mesenteric vein at 10, 20, 40, 80, 160 and 320 mU/(h.kg body weight). During the base-line period, arterial concentrations of glucose, oxygen, nonesterified fatty acids and insulin were not different between control and ractopamine feeding. Arterial urea was lower during ractopamine than during control feeding (5.02 vs. 6.20 mmol/L, respectively, P < 0.01). Net release of glucose by liver and net uptake of glucose by the hindlimb were not affected by treatment. Similarly, net release of insulin by PDV and net uptake of insulin by liver were not affected by treatment. The Rmax and ED50 for steady-state glucose infusion rate, total glucose entry, hepatic glucose production and hindlimb glucose uptake did not differ between treatments. There was a trend for a lower ED50 in hindlimb with ractopamine treatment (P < 0.13). These data do not support a change in sensitivity or responsiveness of tissues to insulin as a major component of the mechanism of action of ractopamine.

Effects of exogenous somatotropin on whole-body glycemic response to insulin in young preruminant and ruminant lambs

The purpose of this study was to determine the effects of exogenous recombinant bovine somatotropin (bST) treatment on whole-body glycemic responsiveness and sensitivity to exogenous insulin in preruminant and ruminant lambs. Twelve milk-fed (MF) and 12 ruminating (RUM) wether lambs weighing 20 +/- 0.6 kg were assigned to one of four treatment groups: MF control, MF plus bST, RUM control, and RUM plus bST. Lambs received a daily subcutaneous injection of 160 micrograms of sometribove (recombinant methionyl bST) bST/kg live weight or the equivalent volume of sterile water (control) for 10 d. The MF lambs had higher plasma insulin and nonessential fatty acids and lower acetate concentrations than RUM lambs (all P < 0.05). Plasma insulin-like growth factor concentrations were similar in both. The administration of bST raised plasma insulin-like growth factor-1 (P < 0.001) and insulin (P < 0.05) in MF and RUM lambs, but with greater effect in MF lambs (P < 0.01 and P < 0.1, respectively). Six successive dose-incremented insulin challenges (50, 100, 200, 300, 500, and 700 mU/kg body weight) were performed two per day on Days 8, 9, and 10 of treatment. Dose-response curves for absolute decline in glucose concentration from preinjection baseline to nadir were used to characterize whole-body responsiveness and sensitivity (ED50) to insulin. Somatotropin treatment increased insulin ED50 values 64 and 70% (P < 0.07) in RUM and MF lambs, respectively, suggesting that sensitivity to insulin was reduced. Insulin ED50 values were 40% higher in MF than in RUM lambs (P < 0.05). Insulin clearance rates increased with each dose increment to 300 mU/kg body weight (P = 0.001) and were 50% lower in bST-treated MF lambs than in all other treatment groups (P < 0.05). Results suggest that somatotropin modulates the insulin control of glucose homeostasis similarly in preruminant and ruminant lambs by decreasing sensitivity but not maximum responsiveness.

Temporal pattern of skeletal muscle changes in lambs fed cimaterol

The objectives of this study were to compare the efficacy of 3-week vs 6-week dietary administration of the beta-adrenergic agonist cimaterol on skeletal muscle growth, and to measure the changes in muscle nucleic acid and protein concentration and content to provide evidence regarding the mechanism(s) by which cimaterol stimulates muscle hypertrophy in growing ruminants. Two groups of 12 Dorset or Dorset-Finn cross ram lambs weighing 36 kg or 33 kg were assigned to treatment intervals of 3 or 6 weeks, respectively. Lambs within each weight group were randomly assigned to receive 0 or 10 ppm cimaterol in a complete mixed diet fed ad libitum. Initial live weights and treatment periods were chosen to achieve similar slaughter weights. Cimaterol increased the mass of three hind leg muscles 30% and 25% on average (both P less than .001) with 3- and 6-week administration, respectively, resulting in identical average muscle weights of treated lambs at both treatment intervals. The mean mass of these 3 muscles, expressed as a percentage of body weight, was increased 18.6% (P less than .001) at both treatment intervals. RNA concentration and content of the semitendinosus muscle were increased 24.8% (P less than .01) and 84.6% (P less than .001), respectively, after 3 weeks of treatment, but neither was significantly different from controls after 6 weeks. DNA concentration in the muscle was reduced 42% (P less than .05) with 3-week cimaterol administration, and was 25% less than controls (P greater than .05) in lambs fed cimaterol for 6 weeks. Total DNA content of the semitendinosus was unchanged at either treatment interval.(ABSTRACT TRUNCATED AT 250 WORDS)